These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 29285538)

  • 1. Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.
    Waxman AJ; Clasen S; Hwang WT; Garfall A; Vogl DT; Carver J; O'Quinn R; Cohen AD; Stadtmauer EA; Ky B; Weiss BM
    JAMA Oncol; 2018 Mar; 4(3):e174519. PubMed ID: 29285538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
    Cornell RF; Ky B; Weiss BM; Dahm CN; Gupta DK; Du L; Carver JR; Cohen AD; Engelhardt BG; Garfall AL; Goodman SA; Harrell SL; Kassim AA; Jadhav T; Jagasia M; Moslehi J; O'Quinn R; Savona MR; Slosky D; Smith A; Stadtmauer EA; Vogl DT; Waxman A; Lenihan D
    J Clin Oncol; 2019 Aug; 37(22):1946-1955. PubMed ID: 31188726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
    Siegel D; Martin T; Nooka A; Harvey RD; Vij R; Niesvizky R; Badros AZ; Jagannath S; McCulloch L; Rajangam K; Lonial S
    Haematologica; 2013 Nov; 98(11):1753-61. PubMed ID: 23935022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolomic signatures of carfilzomib-related cardiotoxicity in patients with multiple myeloma.
    Shabnaz S; Nguyen TN; Williams R; Rubinstein SM; Garrett TJ; Tantawy M; Fradley MG; Alomar ME; Shain KH; Baz RC; Lenihan D; Cornell RF; Lu Q; Gong Y
    Clin Transl Sci; 2024 May; 17(5):e13828. PubMed ID: 38783568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.
    Chari A; Stewart AK; Russell SD; Moreau P; Herrmann J; Banchs J; Hajek R; Groarke J; Lyon AR; Batty GN; Ro S; Huang M; Iskander KS; Lenihan D
    Blood Adv; 2018 Jul; 2(13):1633-1644. PubMed ID: 29991494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis.
    Shah C; Bishnoi R; Jain A; Bejjanki H; Xiong S; Wang Y; Zou F; Moreb JS
    Leuk Lymphoma; 2018 Nov; 59(11):2557-2569. PubMed ID: 29465266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials.
    Ball S; Behera TR; Anwer F; Chakraborty R
    Ann Hematol; 2020 Jun; 99(6):1265-1271. PubMed ID: 32382772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
    Jagannath S; Vij R; Stewart AK; Trudel S; Jakubowiak AJ; Reiman T; Somlo G; Bahlis N; Lonial S; Kunkel LA; Wong A; Orlowski RZ; Siegel DS
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):310-8. PubMed ID: 23040437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma.
    Tantawy M; Langaee T; Wang D; Rubinstein SM; Cornell RF; Lenihan D; Fradley MG; Gong Y
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.
    Bringhen S; Milan A; D'Agostino M; Ferri C; Wäsch R; Gay F; Larocca A; Offidani M; Zweegman S; Terpos E; Goldschmidt H; Cavo M; Ludwig H; Driessen C; Auner HW; Caers J; Gramatzki M; Dimopoulos MA; Boccadoro M; Einsele H; Sonneveld P; Engelhardt M
    J Intern Med; 2019 Jul; 286(1):63-74. PubMed ID: 30725503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib.
    Zhao F; Yang B; Wang J; Zhang R; Liu J; Yin F; Xu W; He C
    Drug Des Devel Ther; 2018; 12():1525-1531. PubMed ID: 29881259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR.
    Takezako N; Shibayama H; Handa H; Hagiwara S; Ozaki S; Suzuki K; Kosugi H; Ri M; Sugiura I; Choi I; Miyamoto T; Iida S
    Int J Hematol; 2021 Feb; 113(2):219-230. PubMed ID: 33037990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infection risk with carfilzomib in multiple myeloma: a systematic review and meta-analysis of randomised controlled trials.
    Wongsaengsak S; Kopel J; Behera TR; Chakraborty R; Ball S
    Br J Haematol; 2020 Jul; 190(2):e95-e97. PubMed ID: 32400886
    [No Abstract]   [Full Text] [Related]  

  • 14. Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis.
    Latif A; Kapoor V; Lateef N; Ahsan MJ; Usman RM; Malik SU; Ahmad N; Rosko N; Rudoni J; William P; Khouri J; Anwer F
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):30-45. PubMed ID: 33845729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
    Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
    Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Carfilzomib-Associated Cardiac Adverse Events.
    Mikhael J
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):241-5. PubMed ID: 26907720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
    Danhof S; Schreder M; Rasche L; Strifler S; Einsele H; Knop S
    Eur J Haematol; 2016 Jul; 97(1):25-32. PubMed ID: 26331915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".
    Mian HS; Fiala MA; Sanchez L; Vij R; Wildes TM
    Ann Hematol; 2021 May; 100(5):1261-1266. PubMed ID: 33475778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.